Psoriasis Market Outlook 2025-2034: Market Share, and Growth Analysis

The Psoriasis Market is valued at USD 24.4 billion in 2025 and is projected to grow at a CAGR of 12.5% to reach USD 70.7 billion by 2034.

Psoriasis Market Overview

The psoriasis market encompasses a wide range of therapies aimed at managing this chronic, immune-mediated skin disorder characterized by red, scaly plaques and systemic inflammation. Psoriasis affects over 125 million people globally and significantly impacts quality of life, often leading to comorbidities such as psoriatic arthritis, cardiovascular disease, and depression. Treatment approaches vary based on disease severity and include topical agents, phototherapy, systemic drugs, and biologics targeting key immune pathways such as TNF-α, IL-17, IL-12/23, and IL-23. With the emergence of targeted biologics and small molecule therapies, the market has transitioned toward more personalized, long-term disease management. Increasing awareness, earlier diagnosis, improved reimbursement frameworks, and the expansion of patient support programs have all contributed to greater adoption of advanced therapies. While biologics dominate the moderate-to-severe segment, there is also robust demand for effective, non-invasive topical treatments in mild cases, offering opportunities across both specialty and primary care settings.

The psoriasis market experienced substantial progress, particularly in biologics and oral therapies. New IL-23 inhibitors demonstrated sustained efficacy with fewer dosing requirements, gaining strong traction among physicians and patients seeking long-term remission with minimal side effects. Additionally, TYK2 inhibitors emerged as a promising new class, offering an oral alternative to injectable biologics for moderate-to-severe cases. Companies also expanded real-world evidence studies to highlight comparative effectiveness and safety, helping differentiate newer therapies in an increasingly competitive landscape. Patient-centered care models saw increased adoption, with digital platforms being used for disease monitoring, tele-dermatology consultations, and treatment adherence tracking. Market access improved in several regions, including Latin America and Asia-Pacific, as public health systems prioritized chronic dermatological conditions. Meanwhile, biosimilars entered more mature markets, leading to price competition and increased affordability. Despite these advancements, disparities in access and undertreatment remained prominent issues, especially in rural and low-income populations.

The psoriasis market is expected to evolve through continued innovation in biologics, broader use of biosimilars, and a growing emphasis on holistic care. Next-generation IL-17 and IL-23 inhibitors with enhanced selectivity and safety profiles will likely enter the market, raising the standard of care. Personalized medicine will gain traction, supported by biomarker-driven treatment selection and AI-powered clinical decision tools. The integration of wearable technologies and mobile health apps will further enable remote monitoring of disease activity and treatment outcomes. Research into gut-skin axis and microbiome modulation is expected to yield novel therapeutic pathways, especially for patients with treatment-resistant or comorbid conditions. Global expansion will be fueled by rising awareness, government health initiatives, and increasing dermatology access in underserved regions. As treatment paradigms shift from symptom control to disease modification, the market will prioritize durability, convenience, and patient satisfaction, offering growth opportunities for both pharmaceutical innovators and digital health providers.

Key Insights: Psoriasis Market

• TYK2 inhibitors are emerging as game-changers, offering effective oral treatment options with favorable safety profiles for moderate-to-severe psoriasis patients.
• Patient engagement is being enhanced through digital health platforms offering personalized tracking, medication reminders, and telehealth consultations.
• Real-world evidence is becoming a key differentiator, with pharmaceutical companies investing in long-term outcome studies and quality-of-life metrics.
• Biosimilars are increasingly being adopted across mature markets, reducing treatment costs and expanding access to biologic therapies.
• Microbiome-focused research and gut-skin axis studies are opening new avenues for alternative and adjunctive therapies in difficult-to-treat cases.

• Rising global prevalence of psoriasis and associated comorbidities is driving demand for effective, long-term treatment solutions.
• Advancements in biologics and oral small molecule therapies are enhancing patient outcomes and expanding therapeutic options.
• Improved healthcare access, reimbursement policies, and patient support programs are boosting adoption rates, especially in emerging markets.
• Increased investment in dermatology R&D is fueling innovation and pipeline diversification for novel psoriasis treatments.

• High treatment costs, particularly for biologics, and inconsistent reimbursement policies across regions continue to limit access for many patients, leading to undertreatment and disease burden disparities.

Psoriasis Market Segmentation

By Drug class

• Interleukin Inhibitors
• Corticosteroids
• Anti-Inflammatory
• Tumor Necrosis Factor Inhibitor

By Drug Types

• Small molecules
• Biologics
  

  By Disease Indication

  • Plaque Psoriasis
  • Nail Psoriasis
  • Guttate Psoriasis
  • Pustular Psoriasis
  • Erythrodermic Psoriasis

  By Route Of Administration

  • Oral
  • Tropical
  • Injectable

  By Distribution Channel

  • Hospitals
  • Retail Pharmacies
  • E-Commerce

  Key Companies Analysed

  • AbbVie Inc.
  • Pfizer Inc.
  • Novartis AG
  • Eli Lilly and Company
  • Celgene Corporation
  • Johnson & Johnson
  • Amgen Inc.
  • Boehringer Ingelheim GmbH
  • Merck & Co. Inc.
  • Janssen Biotech Inc.
  • Takeda Pharmaceutical Company Limited
  • Stiefel Laboratories Inc.
  • AstraZeneca Inc.
  • Union Chimique Belge SA
  • Sun Pharmaceutical Industries Ltd.
  • Forward Pharma AS
  • Almirall SA
  • Bausch Health Companies Inc.
  • Biogen Inc.
  • Biocon Biopharmaceuticals Pvt. Ltd.
  • Celltrion Inc.
  • Dr.Reddy's Laboratories Inc.
  • Arcutis Biotherapeutics Inc.
  • Bayer AG
  • Bristol Myers Squibb Co.
  • Dermira Inc.
  • Galderma SA
  • GlaxoSmithKline Plc
  • Incyte Pharmaceuticals Corp.
  • LEO Pharmacy

  Psoriasis Market Analytics

  The report employs rigorous tools, including Porter’s Five Forces, value chain mapping, and scenario-based modeling, to assess supply-demand dynamics. Cross-sector influences from parent, derived, and substitute markets are evaluated to identify risks and opportunities. Trade and pricing analytics provide an up-to-date view of international flows, including leading exporters, importers, and regional price trends.
  
  Macroeconomic indicators, policy frameworks such as carbon pricing and energy security strategies, and evolving consumer behavior are considered in forecasting scenarios. Recent deal flows, partnerships, and technology innovations are incorporated to assess their impact on future market performance.
  
  

  Psoriasis Market Competitive Intelligence

  The competitive landscape is mapped through proprietary frameworks, profiling leading companies with details on business models, product portfolios, financial performance, and strategic initiatives. Key developments such as mergers & acquisitions, technology collaborations, investment inflows, and regional expansions are analyzed for their competitive impact. The report also identifies emerging players and innovative startups contributing to market disruption.
  
  Regional insights highlight the most promising investment destinations, regulatory landscapes, and evolving partnerships across energy and industrial corridors.
  
  

  Countries Covered

  • North America - Psoriasis market data and outlook to 2034
    • United States
    • Canada
    • Mexico
    
    
  • Europe - Psoriasis market data and outlook to 2034
    • Germany
    • United Kingdom
    • France
    • Italy
    • Spain
    • BeNeLux
    • Russia
    • Sweden
    
    
  • Asia-Pacific - Psoriasis market data and outlook to 2034
    • China
    • Japan
    • India
    • South Korea
    • Australia
    • Indonesia
    • Malaysia
    • Vietnam
    
    
  • Middle East and Africa - Psoriasis market data and outlook to 2034
    • Saudi Arabia
    • South Africa
    • Iran
    • UAE
    • Egypt
    
    
  • South and Central America - Psoriasis market data and outlook to 2034
    • Brazil
    • Argentina
    • Chile
    • Peru

  Research Methodology

  This study combines primary inputs from industry experts across the Psoriasis value chain with secondary data from associations, government publications, trade databases, and company disclosures. Proprietary modeling techniques, including data triangulation, statistical correlation, and scenario planning, are applied to deliver reliable market sizing and forecasting.
  
  

  Key Questions Addressed

  • What is the current and forecast market size of the Psoriasis industry at global, regional, and country levels?
  • Which types, applications, and technologies present the highest growth potential?
  • How are supply chains adapting to geopolitical and economic shocks?
  • What role do policy frameworks, trade flows, and sustainability targets play in shaping demand?
  • Who are the leading players, and how are their strategies evolving in the face of global uncertainty?
  • Which regional “hotspots” and customer segments will outpace the market, and what go-to-market and partnership models best support entry and expansion?
  • Where are the most investable opportunities - across technology roadmaps, sustainability-linked innovation, and M&A - and what is the best segment to invest over the next 3-5 years?

  Your Key Takeaways from the Psoriasis Market Report

  • Global Psoriasis market size and growth projections (CAGR), 2024-2034
  • Impact of Russia-Ukraine, Israel-Palestine, and Hamas conflicts on Psoriasis trade, costs, and supply chains
  • Psoriasis market size, share, and outlook across 5 regions and 27 countries, 2023-2034
  • Psoriasis market size, CAGR, and market share of key products, applications, and end-user verticals, 2023-2034
  • Short- and long-term Psoriasis market trends, drivers, restraints, and opportunities
  • Porter’s Five Forces analysis, technological developments, and Psoriasis supply chain analysis
  • Psoriasis trade analysis, Psoriasis market price analysis, and Psoriasis supply/demand dynamics
  • Profiles of 5 leading companies - overview, key strategies, financials, and products
  • Latest Psoriasis market news and developments

  Additional Support

  With the purchase of this report, you will receive:
  
  • An updated PDF report and an MS Excel data workbook containing all market tables and figures for easy analysis.
  • 7-day post-sale analyst support for clarifications and in-scope supplementary data, ensuring the deliverable aligns precisely with your requirements.
  • Complimentary report update to incorporate the latest available data and the impact of recent market developments.

This product will be delivered within 1-3 business days.